Description:
This active molecular also known as AC220 and AC010220, is developed as a new second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM, ten fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Now Quizartinib is in Phase-III clinical trials in Acute myeloid leukaemia.
- Molecular Weight:560.67
- Purity:98%
Molecular Formula:
C29H32N6O4S
Canonical SMILES:
O=C(NC1=CC=C(C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)C=C1)NC6=NOC(C(C)(C)C)=C6
InChI:
1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)
InChIKey:
CVWXJKQAOSCOAB-UHFFFAOYSA-N
Solubility:
Soluble in DMSO
Appearance:
Solid powder
Application:
treatment of Acute myeloid leukaemia(AML).
Storage: -20°C Freezer
Synonyms:
1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea; AC220; AC 220; AC-220; AC010220; AC-010220; AC 010220; AC010220; Quizartinib Más detalles se encuentran
aquí